A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: In vitro and in vivo characterization

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 88-101

  Zhao, Ji Hui ^a   Fu, Ji Hua ^b   Wang, Shu Ming ^c   Su, Chang Hai ^b   Shan, Ying ^b   Kong, Shu Jia ^b   Wang, Yuan ^b   Lu, Wan Liang ^a   Zhang, Hua ^a   Zhang, Shuang ^c   Li, Lin ^c   Zhang, En Hong ^c   Wang, Li ^c   Pei, Qiu Ling ^d   Wang, Jian Cheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c Beijing Kangbeide Pharmaceutical Development Company Limited   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Bisoprolol; Hypertension; Isosorbide dinitrate; Pharmacodynamics; Pharmacokinetics; Transdermal delivery

Indexed keywords

BISOPROLOL; BISOPROLOL PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENTIATION; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PATCH TEST; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; BISOPROLOL; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; DIFFUSION CHAMBERS, CULTURE; DISEASE MODELS, ANIMAL; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG COMPOUNDING; GUINEA PIGS; HEART RATE; HYPERTENSION, RENOVASCULAR; ISOSORBIDE DINITRATE; MALE; NITRIC OXIDE DONORS; RABBITS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION; SOLUBILITY; TISSUE CULTURE TECHNIQUES; VASODILATOR AGENTS;

EID: 34248529725     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.12.030     Document Type: Article

References (39)

1. Aqil M., Zafar S., Ali A., and Ahmad S. Transdermal drug delivery of labetolol hydrochloride: system development, in vitro; ex vivo and in vivo characterization. Curr. Drug Deliv. 2 (2005) 125-131
2. Assinder D.F., Chasseaud L.F., and Taylor T. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. J. Pharm. Sci. 66 (1977) 775-778
3. Audet M.C., Moreau M., Koltun W.D., Waldbaum A.S., Shangold G., Fisher A.C., and Creasy G.W. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. ORTHO EVRA/EVRA 004 Study Group. JAMA 5 (2001) 2347-2354
4. Babu R.J., and Pandit J.K. Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin. Drug Deliv. 12 (2005) 165-169
5. Baker J.G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 144 (2005) 317-322
6. Bosch J., Garcia-Pagan J.C., Feu F., Luca A., Fernandez M., Pizcueta P., and Rodes J. New approaches in the pharmacologic treatment of portal hypertension. J. Hepatol. 17 (1993) S41-S45
7. Braza A.J., Modamio P., Lastra C.F., and Marino E.L. Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. Biomed. Chromatogr. 16 (2002) 517-522
8. Brodde O.E. Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies. J. Cardiovasc. Pharmacol. 8 (1986) S29-S35
9. Buhring K.U., Sailer H., Faro H.P., Leopold G., Pabst J., and Garbe A. Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. J. Cardiovasc. Pharmacol. 8 (1986) S21-S28
10. Burrell L.M., Risvanis J., Phillips P.A., Naitoh M., and Johnston C.I. Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension. Clin. Exp. Hypertens. 19 (1997) 981-991
11. Chamontin B. The best of hypertension 2005. Arch. Mal. Coeur. Vaiss. 99 (2006) 35-41
12. de Muinck E., Wagner G., vd Ven L.L., and Lie K.I. Comparison of the effects of two doses of bisoprolol on exercise tolerance in exercise-induced stable angina pectoris. Eur. Heart J. 8 (1987) 31-35
13. Draize J.H., Woodard G., and Calvery H.O. Methods for the study of irritation and toxicity of substances applied to the skin and mucous membrane. J. Pharmacol. Exp. Ther. 82 (1944) 377-390
14. Fu J.H., and Luo Y.M. BESN system of multi-channel tail-artery blood pressure measurement. J. China Pharm. Univ. 35 (2004) 466-469
15. Fung H.L. Nitrate formulations and drug delivery systems-an overview. Z. Kardiol. 74 (1985) 4-9
16. Gabiga H., Cal K., and Janicki S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system. Int. J. Pharm. 199 (2000) 1-6
17. Garcia-Pagan J.C., Navasa M., Bosch J., Bru C., Pizcueta P., and Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 11 (1990) 230-238
18. Garcia-Pagan J.C., Feu F., Bosch J., and Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann. Intern. Med. 114 (1991) 869-873
19. Harting J., Becker K.H., Bergmann R., Bourgois R., Enenkel H.J., Fuchs A., Jonas R., Lettenbaur H., Minck K.O., and Schelling P. Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol. Arzneimittelforschung 36 (1986) 200-208
20. Hoyert D.L., Kung H.C., and Smith B.L. Deaths: preliminary data for 2003. Natl. Vital Stat. Rep. 53 (2005) 1-48
21. Ishibashi T., Himeno M., Kubota K., Matsubara T., Hori T., Ozaki K., Yamazoe M., Aizawa Y., Yoshida J., and Nishio M. Decrease in plasma NOx concentration by isosorbide dinitrate, an organic nitrate ester. J. Cardiovasc. Pharmacol. 41 (2003) 40-48
22. Johnson K.I., Gladigau V., and Schnelle K. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man. Arzneimittelforschung 31 (1981) 1026-1029
23. Jung J.Y., Lee J.U., and Kim W.J. Enhanced activity of central adrenergic neurons in two-kidney, one clip hypertension in Sprague-Dawley rats. Neurosci. Lett. 369 (2004) 14-18
24. Ke G.M., Wang L., Xue H.Y., Lu W.L., Zhang X., Zhang Q., and Guo H.Y. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. Biol. Pharm. Bull. 28 (2005) 305-310
25. Kim J., and Kitakaze M. Prevention and treatment of the hypersensitive organopathy-the necessity of cardiovascular protection. Nippon Rinsho 62 (2004) 120-127
26. Kokubo T., Sugibayashi K., and Morimoto Y. Interaction between drugs and pressure-sensitive adhesives in transdermal therapeutic systems. Pharm. Res. 11 (1994) 104-107
27. Lancaster S.G., and Sorkin E.M. Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 36 (1988) 256-285
28. Laufen H., and Leitold M. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray. Arzneimittelforschung 42 (1992) 931-935
29. Liang W.Q. In: Lu B. (Ed). Transdermal Patches in New Techniques and New Dosage Forms of Drugs. 2nd ed. (2005), People's Medical Publishing House, Beijing 568-569
30. Modamio P., Lastra C.F., and Marino E.L. A comparative in vitro study of percutaneous penetration of beta-blockers in human skin. Int. J. Pharm. 194 (2000) 249-259
31. Orban Schiopu A.M., Balas B.I., and Diculescu M. The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension. Rom. J. Gastroenterol. 14 (2005) 123-127
32. Pfister W.R., and Hsieh D.S. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations. Med. Device Technol. (1990) 148-155
33. Pfister W.R., and Hsieh D.S. Permeation enhancers compatible with transdermal drug delivery systems: part II: system design considerations. Med. Device Technol. 1 (1990) 28-33
34. Ranade V.V. Drug delivery systems 6. Transdermal drug delivery. J. Clin. Pharmacol. 31 (1991) 401-418
35. Ruan L.P., Liang B.W., Tao J.Z., and Yin C.H. Transdermal absorption of nitrendipine from adhesive patches. Control Rel. 20 (2006) 231-236
36. Schaumann W. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. Int. J. Clin. Pharmacol. Ther. Toxicol. 27 (1989) 445-453
37. Taylor T., Chasseaud L.F., Major R.M., Leaf F.C., Bonn R., Darragh A., and Lambe R.F. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. Biopharm. Drug Dispos. 6 (1985) 119-129
38. Uusitalo A. Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving beta-blockers. Drugs 33 (1987) 111-117
39. Walker R.B., and Smith E.W. The role of percutaneous penetration enhancers. Adv. Drug Deliv. Rev. 18 (1996) 295-301